Lim SCL et al., 2022-04: Open-label randomized trial in 490 high-risk patients in Malaysia: ivermectin 0.4 mg/kg daily for five days did not prevent progression to severe disease (21.6% vs 17.3%).
In this randomized clinical trial of high-risk patients with mild to moderate COVID-19, ivermectin treatment during early illness did not prevent progression to severe disease.
Lim SCL et al., 2022-04: Open-label randomized trial in 490 high-risk patients in Malaysia: ivermectin 0.4 mg/kg daily for five days did not prevent progression to severe disease (21.6% vs 17.3%). Open-label randomized clinical trial, 20 public hospitals and a quarantine centre, Malaysia, May-October 2021; N=490 analysed (241 ivermectin, 249 standard care), patients 50 and older with comorbidities and mild-moderate disease; ivermectin 0.4 mg/kg body weight daily for 5 days plus standard of care vs standard of care alone. Progression to severe disease 21.6% vs 17.3%; mechanical ventilation 1.7% vs 4.0% (RR 0.41, 0.13-1.30); 28-day in-hospital death 1.2% vs 4.0% (RR 0.31, 0.09-1.11); diarrhoea more common with ivermectin (5.8% vs 1.6%). Disclosures: none reported. NCT04920942. Study type: randomized trial.
